Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). AbCellera Biologics's share price for the quarter that ended in Mar. 2024 was $4.53. AbCellera Biologics's Shares Outstanding (EOP) for the quarter that ended in Mar. 2024 was 293.62 Mil. Therefore, AbCellera Biologics's market cap for the quarter that ended in Mar. 2024 was $1,330.10 Mil.
AbCellera Biologics's quarterly market cap
increased
from Sep. 2023 ($1,332.98 Mil) to Dec. 2023 ($1,660.61 Mil) but then
declined
from Dec. 2023 ($1,660.61 Mil) to Mar. 2024 ($1,330.10 Mil).
AbCellera Biologics's annual market cap
declined
from Dec. 2021 ($4,050.58 Mil) to Dec. 2022 ($2,905.81 Mil) and
declined
from Dec. 2022 ($2,905.81 Mil) to Dec. 2023 ($1,660.61 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. AbCellera Biologics's Enterprise Value for Today is $487.11 Mil.
AbCellera Biologics Market Cap Historical Data
The historical data trend for AbCellera Biologics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of AbCellera Biologics's Market Cap
For the Biotechnology subindustry, AbCellera Biologics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AbCellera Biologics's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AbCellera Biologics's Market Cap distribution charts can be found below:
* The bar in red indicates where AbCellera Biologics's Market Cap falls into.
AbCellera Biologics Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
AbCellera Biologics's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AbCellera Biologics (NAS:ABCL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
AbCellera Biologics Market Cap Related Terms
Thank you for viewing the detailed overview of AbCellera Biologics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
AbCellera Biologics (AbCellera Biologics) Business Description
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the most effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and leading pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABCL has been successfully added to your 